Who we are
SCAD creates human cell solutions that enable more efficient, and safer drug discovery and development processes, which will ultimately benefit patients and the society at large. We develop novel 3D-cell culture devices that predict potential toxicities and efficacies of drugs and compounds on human biology in vitro.
- December 21, 2018
November 20, 2018
Our Chief Advisor Prof. Norio Nakatsuji will serve as a Conference Chair and will hold the Opening Lecture at the "Cell Therapy Asia 2018" conference in Kobe, Japan (December 6-7, 2018)Read more
September 24, 2018
Our Chief Advisor Prof. Norio Nakatsuji has been selected as a keynote speaker at this year’s SelectBio conference on Stem Cells in Drug Discovery & Toxicity in San Diego, CA, USA (October 4-5, 2018)Read more
- September 20, 2018
- August 14, 2018
Starting our predictive drug toxicology and efficacy platform is the SCAD-MT ™ cardiomyocyte, which is a ready-to-use nanofiber-based device with our physiologically relevant human iPS cell-derived cardiac micro-tissues (MT).
The 3D culture environment of SCAD-MT ™ cardiomyocyte leads to functional and mature cardiac microtissues with multi-layered, highly oriented, more human-like structures that ensure the consistent prediction of toxicities and efficacies of drugs in vitro.
Our expertise in stem cells and nanofiber materials allows us to develop cell devices that fine-tune the unique properties of organ tissues to scaffold materials. Such optimum cell-material combinations result in enhanced levels of cell functionality and maturation, and ultimately in predictive and consistent cell devices and assays for drug discovery and development, an in vitro toxicology. In particular, SCAD’s cell products offer remarkable benefits for contractility and long-term chronic toxicity studies.